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Angiotensin II upregulates the expression of LOX-1, a
recently identified oxidized low-density lipoprotein receptor
controlled by redox state which in turn upregulates
angiotensin II activity on its activation. To test whether
interruption of this positive feedback loop might reduce
angiotensin II-induced hypertension and subsequent renal
injury, we studied LOX-1 knockout mice. After infusion with
angiotensin II for 4 weeks systolic blood pressure gradually
increased in the wild-type mice; this rise was significantly
attenuated in the LOX-1 knockout mice. Along with the rise
in systolic blood pressure, renal function (blood urea
nitrogen and creatinine) decreased in the wild-type mice, but
the deterioration of function was significantly less in the LOX-
1 knockout mice. Glomerulosclerosis, arteriolar sclerosis,
tubulointerstitial damage, and renal collagen accumulation
were all significantly less in the LOX-1 knockout mice. The
reduction in collagen formation was accompanied by a
decrease in connective tissue growth factor mRNA,
angiotensin type 1 receptor expression, and phosphorylation
of p38 and p44/42 mitogen-activated protein kinases.
Expression of endothelial nitric oxide synthase was increased
in the kidneys of the LOX-1 knockout mice compared to the
wild-type mice. Overall, our study suggests that LOX-1 is a
key modulator in the development of angiotensin II-induced
hypertension and subsequent renal damage.
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Glomerulosclerosis is thought to have a central pathogenetic
role in the progression from chronic glomerulopathies to
end-stage renal disease.1 It is characterized by relentless renal
fibrosis. Stress states, such as sustained hypertension, result in
glomerulosclerosis. Oxidant stress has been implicated in
atherosclerosis2 and glomerulosclerosis.3 LOX-1 has recently
been identified as an oxidized low-density lipoprotein
(ox-LDL) receptor that is upregulated by redox state4 and
is abundantly expressed in vascular endothelial cells and the
renal tissues.5 LOX-1 is upregulated in the kidneys of salt-
loaded Dahl salt-sensitive rats and chronic renal failure rats
and parallels glomerulosclerotic changes and renal dysfunc-
tion, suggesting a possible link between LOX-1 and the
progression to glomerulosclerosis and renal failure.5
The renin–angiotensin system and its effector hormone,
angiotensin II (Ang II), have well-known endocrine proper-
ties which contribute to renal fibrosis.6 Previous studies
showed that Ang II through type 1 (AT1) receptor activation
stimulates LOX-1 expression.7 In turn, LOX-1 activation
upregulates AT1 receptor expression.8 Activation of both AT1
and LOX-1 receptors induces a state of oxidative stress.4
Recently, we used a mouse model of LOX-1 deficiency
(hereafter called LOX-1 knockout mice) and showed that
targeted deletion of LOX-1 reduces Ang II-induced hyperten-
sion and subsequent cardiac remodeling.9 To gain further
insight into the role of LOX-1 in hypertensive renal injury, we
collected the kidneys of these mice and studied the effect of
LOX-1 deletion on Ang II-mediated renal injury.
RESULTS
Blood pressure in response to Ang II
Basal systolic blood pressure was similar in the wild-type and
LOX-1 knockout mice and remained unchanged in all saline-
treated mice. On the other hand, systolic blood pressure
progressively increased during the Ang II infusion period,
reaching a peak value on day 14 and remaining at plateau
through day 28 in the wild-type mice (Figure 1). The rise in
blood pressure was less in the LOX-1 knockout mice (Po0.01
vs wild-type mice), despite infusion with the same dose of
Ang II.
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Renal morphology
Typical histological photomicrographs of glomerulosclerosis,
arterio-arteriolar sclerosis, and tubulointerstitial damage are
shown in Figure 2 (left panel). Renal injury scores are shown
in Figure 2 (middle panel). Glomerulosclerosis, arterio-
arteriolar sclerosis, and tubulointerstitial damage were
significantly increased after 28-day infusion of Ang II in the
wild-type mice (Po0.01 vs saline-infused mice). The LOX-1
knockout mice, given Ang II infusion, exhibited less
glomerulosclerosis, arterio-arteriolar sclerosis, and tubuloin-
terstitial damage (Po0.01 vs wild-type mice).
Renal fibrosis and injury following sustained hypertension
and effect of LOX-1 deletion
Sustained hypertension and resultant renal fibrosis is
characterized by abundant accumulation of matrix proteins
in the extracellular space.10 We, therefore, determined the
accumulation of collagen in multiple sections of kidneys
from different animal groups. Results of Masson trichrome
and Picro-sirius red staining were similar. In the wild-type
mice, sustained hypertension following Ang II infusion
resulted in a significant increase in collagen accumula-
tion (Figure 2, right) (Po0.01 vs saline-infused mice). In
contrast, the LOX-1 knockout mice showed less increase in
collagen accumulation despite Ang II infusion (Po0.01 vs
wild-type mice).
As shown in Figure 3, the levels of plasma creatinine and
BUN were increased in the Ang II-infused wild-type mice
(Po0.01 vs saline-infused mice). However, LOX-1 knockout
mice showed less increase in the plasma creatinine and BUN
levels despite Ang II infusion (Po0.01 vs wild-type mice).
Expression of AT1 receptor, MAPKs, CTGF, and eNOS induced
by Ang II infusion, and effect of LOX-1 deletion
Most of the cardiovascular actions of Ang II have been
attributed to AT1 receptor activation.6 We found that AT1
receptor mRNA expression increased in kidneys after
infusion of Ang II in the wild-type mice (Po0.01 vs saline-
infused mice). However, Ang II-infused LOX-1 KO mice
showed less increase in AT1 receptor expression (Po0.01 vs
wild-type mice) (Figure 4).
The phosphorylation of MAPKs has been linked to the
development of renal injury and fibrosis.10 The protein levels
of p38 and p44/42 MAPKs were unchanged in response to
Ang II infusion, but their phosphorylation increased
significantly following Ang II infusion (Po0.01 vs saline-
infused mice). Importantly, LOX-1 knockout mice exhibited
less phosphorylation of MAPKs despite Ang II infusion
(Po0.01 vs wild-type mice) (Figure 5).
CTGF is a fibrosis mediator.10 As shown in Figure 5, the
expression of CTGF increased after infusion of Ang II
(Po0.01 vs saline-infused wild-type mice). However, LOX-1
knockout mice given Ang II infusion exhibited less increase
in the expression of CTGF (Po0.01 vs wild-type mice)
Our recent study showed that endothelium-dependent
relaxation of aorta as well as eNOS expression are preserved
in the LOX-1 knockout mice fed high cholesterol diet.11 In
this study, we measured eNOS expression in kidney, and
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Figure 1 | Systolic blood pressure rise in response to angiotensin II (Ang II) infusion in wild-type (WT) and LOX-1 knockout (KO)
mice. LOX-1 deletion attenuated blood pressure response to Ang II infusion. Data (in mean±s.e.) from 6–12 animals.
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found that baseline eNOS expression in the LOX-1 knockout
mice was higher than in the wild-type mice. eNOS expression
decreased further after Ang II infusion in the wild-type mice
(Po0.01); in contrast, LOX-1 knockout mice kidneys showed
a smaller decrease in the expression of eNOS after Ang II
infusion (Po0.01 vs wild-type mice, Figure 5).
DISCUSSION
There are a host of studies showing inappropriate activation
of the intrarenal renin–angiotensin system in the pathogen-
esis of hypertension and renal injury. Drug therapies directed
at angiotensin-converting enzyme and AT1 receptor activa-
tion have certainly been shown to attenuate the disease
process. However, there is still significant morbidity and
mortality associated with hypertensive renal disease. Accord-
ingly, it is necessary to understand other mechanisms
responsible for renal injury in hypertension.
Our study shows that renal injury caused by hypertension
is markedly reduced with LOX-1 deletion. The reduction in
renal injury is accompanied by a decrease in AT1 receptor
expression and activation of MAPKs and an increase in eNOS
expression.
The rationale for this study comes from previous
observations that oxidant stress induces LOX-1 expression.4
Ang II through AT1 receptor activation induces LOX-1
expression at transcriptional level.7 In turn, ox-LDL through
LOX-1 upregulates the expression of AT1 receptors.8 These
observations have been the basis of the hypothesis of a cross
talk between oxidant stress, LOX-1, and Ang II in the genesis
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Figure 2 |Renal morphology in mice given Ang II. The left panel shows typical histological photomicrographs of glomerulosclerosis,
arterio-arteriolar sclerosis, and tubulointerstitial damage. Summary of renal injury scores is shown in the middle panel. LOX-1 knockout mice
given Ang II infusion exhibited less glomerulosclerosis, arterio-arteriolar sclerosis, and tubulointerstitial damage (n¼ 5). Staining for collagen
in renal sections is shown in the right panel. Tissue sections were stained with Masson’s trichrome and Picrosirius red. LOX-1 knockout mice
exhibited less increase in collagen accumulation despite Ang II infusion.
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Figure 3 |Measurement of plasma creatinine and blood urea
nitrogen (BUN). LOX-1 knockout mice given Ang II infusion
showed less increase in the plasma levels of creatinine and BUN
(n¼ 6–12).
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of hypertension, atherosclerosis, myocardial ischemia, and
renal injury. In a recent study,9 we documented that Ang II-
mediated hypertension is attenuated in the LOX-1 knockout
mice; in contrast, norepinephrine-mediated hypertension,
which does not involve the expression of LOX-1, is not
affected by LOX-1 deletion. Other studies showed that LOX-1
deletion reduces ischemia-reperfusion injury in the wild-type
mice12 as well as the development of atherosclerosis in the
LDL receptor null mice.11 Now we show that LOX-1 deletion
also reduces markers of renal injury in mice given Ang II. In
keeping with the observation of increased AT1 receptor
expression in the aortic and cardiac tissues in the wild-type
mice given Ang II,9 AT1 receptor expression in kidneys also
increased in the wild-type mice given Ang II infusion.
Importantly, LOX-1 knockout mice exhibited less increase in
AT1 receptor expression despite Ang II infusion. These
findings suggest that Ang II-AT1 receptor-LOX-1 loop is an
important regulator of renal injury.
Oxidant stress induces endothelial injury and causes
downregulation of eNOS expression and activity. These
processes have been implicated in hypertension-induced
renal injury.3 Much of the effect of oxidant stress is mediated
through LOX-1 expression/activation because its deletion
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Figure 4 | Expression of Angiotensin II type 1 receptor (AT1R).
Ang II-infused LOX-1 knockout mice showed less increase in the
expression of AT1R (n¼ 5).
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Figure 5 | Expression of mitogen-activated protein kinases (MAPKs), connective-tissue growth factor (CTGF), and endothelial nitric
oxide synthase (eNOS). Ang II-infused LOX-1 knockout mice exhibited less phosphorylation of MAPKs and less increase in the expression
of CTGF. LOX-1 deletion was associated with a smaller decrease in the expression of eNOS despite Ang II infusion (n¼ 5).
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restores eNOS expression and NO-dependent vasomotor
activity.11 We now show that LOX-1 deletion attenuates the
loss of eNOS expression following Ang II infusion.
Ang II-mediated oxidant stress involves a host of
intracellular signals, including activation of MAPKs.9,13
Although most studies show p38 MAPK activation, others
have encountered enhanced p44/42 MAPK activity in Ang II-
mediated oxidant stress.9,14 An in vitro study showed that ox-
LDL-mediated activation of LOX-1 is associated with p38
MAPK activation suggesting activation of pro-inflammatory
pathways.15 p44/42 MAPK phosphorylation is also mediated
by LOX-1 activation.9,12 This study shows activation of both
p38 and p44/42 isoforms of MAPKs in the renal tissues of
Ang II-infused mice. Interestingly, activation of both iso-
forms of MAPKs was reduced in the LOX-1 knockout mice
despite infusion of Ang II. These data suggest a link between
LOX-1 activation, MAPK activation, and renal injury in vivo.
The extent of renal injury was quantified in this study by
histological changes and measurement of plasma BUN and
creatinine levels, as in earlier studies.16,17 All three markers of
hypertensive renal injury, glomerulosclerosis, arterio-arterio-
lar sclerosis and tubulointerstitial damage, were enhanced in
the hypertensive wild-type mice, and LOX-1 deletion
attenuated these histologic markers of renal injury. Notably,
these alterations in renal structure resulted in a modest, but
significant, reduction in plasma BUN and creatinine levels in
LOX-1 knockout mice (vs wild-type mice).
LOX-1 activation stimulates collagen formation.9,18–20 In
this context, it is significant that renal fibrosis was reduced in
the LOX-1 knockout mice despite Ang II infusion. The
histological evidence was supported by CTGF expression,
which was reduced in the basal state; its rise with the
development of hypertension was also reduced in the LOX-1
knockout mice.
Ando and Fujita21 have emphasized the role of LOX-1 in
rodents with chronic renal injury. Dominguez et al.22 showed
that obese rats, a model of metabolic syndrome in which
hypertension is the dominant feature, show renal enlarge-
ment, intense oxidative stress, lipid accumulation, leukocyte
infiltration, and renal dysfunction and fibrosis. These rats also
show LOX-1 overexpression, and treatment with anti-LOX-1
antibody significantly limits or prevents the detrimental
effects of obesity on renal function. In other studies by this
group,23 isolated proximal tubules from obese diabetic rats
(NRK52E cells) were exposed to ox-LDL in vitro, and these
cells changed their normally quiescent epithelial phenotype
into a pro-inflammatory phenotype. These cells after
exposure to ox-LDL exhibited suppression of anti-inflamma-
tory transcription factor peroxisome proliferator-activated
receptor-delta. In addition, ox-LDL impaired epithelial barrier
function. Urine of obese diabetic rats contained more lipid
peroxides and elevated levels of LOX-1. Levels of ICAM-1 and
focal adhesion kinase, which participate in leukocyte migra-
tion and epithelial dedifferentiation, were also upregulated in
the tubules of diabetic obese rats. All these alterations were
prevented by an anti-LOX-1 antibody. Interestingly, the
protective effects of taurine, eplerenone, and statins against
renal injury have been attributed to LOX-1 suppression in
hypertensive or diabetic rats.16,17,24,25
The present observations suggest that LOX-1 deletion
modulates renal injury induced by Ang II infusion. However,
whether the modulation of renal function is a direct effect of
LOX-1 deletion on renal structures or a result of attenuation
of hypertension cannot be discerned from this study
Nonetheless, amelioration of renal structural changes and
dysfunction by LOX-1 deletion strategy was significant. In
this process, inhibition of AT1 receptor and MAPKs activity
and overexpression of eNOS may have played a putative role.
Further, it was obvious that Ang II-induced renal injury was
not completely abolished by LOX-1 deletion, suggesting that
there are other pathways by which Ang II induces renal
injury. This study also does not rule out the possibility that
the benefit of LOX-1 deletion in this model may be linked to
concomitant alterations in other pathways. In keeping with
this suggestion are our recent observations that LOX-1
inactivation leads to upregulation of immunoglobulins in
cardiomyocytes challenged with Ang II.26
MATERIALS AND METHODS
Animals
C57BL/6 mice (also referred to as wild-type mice) were obtained
from Jackson Laboratories (Bar Harbor, ME, USA). The homo-
zygous LOX-1 knockout mice were developed as described
recently,11 and backcrossed eight times with C57BL/6 strain to
replace the genetic background. Male C57BL/6 and LOX-1 knockout
mice weighing 22–26 g were utilized at 8–10 weeks of age. All animals
received humane care in compliance with the Public Health Service
Policy on Humane Care and Use of Laboratory Animals published
by the National Institutes of Health. These studies were approved by
Institutional Animal Care and Usage Committee.
Infusion of Ang II
An osmotic minipump (Alzet Model 2004) containing saline vehicle,
Ang II (Sigma, St Louis, MO, USA) was implanted into the
subcutaneous space of C57BL/6 and LOX-1 knockout mice
anesthetized with pentobarbital sodium (80mg/kg, i.p.). Ang II
was delivered at an infusion rate of 50 ng/min for 28 days. The
dosage of Ang II was chosen on the basis of published data.27,28
Determination of blood pressure
Systolic blood pressure was measured through a tail-cuff apparatus
(AD Instruments, Bella Vista, NSW, Australia) in conscious mice 3
days before and then on days 0, 2, 5, 9, 14, 21, and 28 after
implantation of a minipump. Systolic blood pressure values were
derived from an average of five measurements per animal at each
time point. Three preliminary training sessions were performed
during 1 week before starting the experiment to ensure accurate
measurements. In preliminary studies, the accuracy of tail cuff was
established by comparing data obtained with biotelemetry system
(Data Sciences, St Paul, MN, USA).
Renal morphology and renal injury score
Kidney sections were stained with hematoxylin and eosin, periodic
acid-Schiff, and periodic acid-methenamine silver. Glomerulosclero-
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sis, arterio-arteriolar sclerosis, and tubulointerstitial damage were
scored as described.16 The pathologist (JM) scored renal injury
according to the method published in Figure 1a of reference 16 while
unaware of source of kidney. Glomerulosclerosis was scored in 100
glomeruli in each section as G0 for a normal glomerulus; G1, mild
sclerosis (o25%); G2, moderate segmental sclerosis (25–50%); G3,
severe segmental sclerosis (50–75%); and G4, global sclerosis.
Arterio-arteriolar sclerosis was scored in 20–30 arteries and
arterioles in each section as A0, normal; A1, thickening of media;
A2, focal hyalinosis with thickening of media; A3, medial thickening
with global hyalinosis; A4, fibrinoid necrosis and/or cellular
hyperplasia with narrowing of arteriolar lumen and/or thrombus
formation. Tubulointerstitial damage was categorized in 25 areas per
section randomly photographed as TI0, normal; TI1, periarterial
fibrosis; TI2, peritubular fibrosis; TI3, hyaline casts with focal
fibrosis; and TI4, focal fibrosis with cellular infiltration in a large
area. The damage score was calculated in five mice in each
group as (0 number of S0þ 1 number of S1þ 2 number of
S2þ 3 number of S3þ 4 number of S4)/(number of S0þ S1þ
S2þ S3þ S4), where S represents glomerulosclerosis, arterio-arteriolar
sclerosis, or tubulointerstitial damage.
Histological evaluation of renal fibrosis
Renal fibrosis was assessed by analysis of collagen accumulation.
Renal tissues were prepared and embedded in paraffin, cut into
5-mm thick sections, and stained with hematoxylin–eosin, Masson’s
trichrome and Picro-sirius red.
Measurement of plasma creatinine and BUN
Plasma creatinine and BUN were determined using a diagnostic
kit from International Bio-Analytical Industries Inc. (Boca Raton,
FL, USA).
Expression analysis
RT-PCR analysis for AT1 receptor was performed as described
previously.20 GAPDH was used as a standard control. The primers
used are as follows. GAPDH: forward, 50-AACTTTGG
CATTGTGGAAGG-30; reverse, 50-ACACATTGGGGGTAGGAACA-
30. AT1 receptor: forward, 50-TCATTTACTTTTATATTGTAA-30;
reverse 50-TGAATTTCATAAGCCTTCTT-30. Expression of p38 and
p44/42 MAPK isoforms was assessed by western analysis using stan-
dard methodologies.13 All primary antibodies were purchased from
Santa Cruz, CA, USA. The relative densities of protein bands were
analyzed by Scan-gel-it.13
RT-PCR analysis for the expression of eNOS and CTGF was
performed as described previously.20 GAPDH was used as a stan-
dard control. The primers used are as follows. GAPDH: forward,
50-GACCACAGTCCATGCCATCACT-30; reverse, 50-TCCACCACCC
TGTTGCTGTAG-30. eNOS: forward 50-CCTTCCGCTACCAGCC
AGA-30; reverse, 50-CAGAGATCTTCACTGCATTGGCTA-3; CTGF:
forward, 5-GAGTGGGTGTGTGACGAGCCCAAGG-30; reverse, 50-ATG
TCTCCGTACATCTTCCTGTAGT-30.
Statistical analysis
Data are presented as mean±s.e. The data regarding the expression
of mRNA and protein and renal injury were analyzed by
Kruskal–Wallis H-test. All other data were analyzed by a one-way
ANOVAwith a Newman–Student–Keul t-test. Four fold comparisons
were performed and an adjusted value of Po0.05 was considered
to be significant. All calculations were performed with SPSS
version 12.0.
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